Gateway 2011: Baxter BioPharma Solutions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Baxter BioPharma Solutions


Baxter Healthcare Corporation
25212 W. Illinois Route 120
Round Lake, IL 60073
Telephone: 800.422.9837 (US), 847.948.4770 (Outside US)
Fax: 847.948.3642
E-mail: biopharmasolutions@baxter.com
Website: baxterbiopharmasolutions.com
Number of Employees: 49,700 globally
Date Founded: 1931

BioPharma Solutions, a business unit of Baxter, partners with pharmaceutical companies to support your commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parenteral products face.

Experience Makes the Difference. With 80 years of parenteral expertise, we can help to navigate the pathway of success for your molecule. Our long-standing history puts unique expertise at your fingertips.

We Understand Parenterals. As a parenterals specialist, BioPharma Solutions offers unique delivery systems and a wide variety of manufacturing solutions to meet complex and traditional sterile manufacturing challenges. In addition, we offer a broad spectrum of support services including formulation and development to help solve the highstakes challenges in today’s complex parenteral marketplace. Our areas of expertise include:

Parenteral Delivery Systems

  • Prefilled Syringes
  • Liquid Vials
  • Lyophilized Vials
  • Cartridges
  • Frozen Premix Systems
  • Liquid Premix Systems
  • BIO-SET Luer System
  • Diluents for Reconstitution
  • Ampoules
  • Powder Filled Vials
  • Sterile Crystallization

Drug Categories

  • Small Molecules
  • Biologics; including Monoclonal Antibodies and Therapeutic Proteins
  • Vaccines; both Adjuvant and Conjugate
  • Cytotoxics
  • Antibody-Drug Conjugates (ADCs)
  • Highly Potent Compounds
  • Cephalosporins/Penicillins

Extensive Network. With more than 50 manufacturing facilities across six continents, Baxter’s global presence provides opportunities for unique manufacturing collaborations to provide the most value for our partners. The power of an extensive global network lies in the coordination of, and efficiencies resulting from, a systemic approach to cGMP manufacturing.

We Take Partnering Seriously. As a partner to over 60 pharmaceutical clients, we realize that successful alliances are critical in this extremely competitive environment. BioPharma Solutions has developed strong organizational capabilities to ensure our partnership provides the value you deserve and expect. Because of this we have been honored with various global distinctions by the industry including “Best Contract Manufacturing Organization” at the Vaccine Industry Excellence Awards and European Outsourcing Award winner for Most Effective Scaleup/Technical Transfer, to name a few.

Ultimately, our goal is to make you feel confident and secure choosing BioPharmaSolutions as a partner—helping you to avoid the unexpected and guiding you through marketplace complexities so you can achieve the full potential of your molecule.

BioPharma Solutions provides our clients with confidence of delivery, service, and integrity—we know the work we do is ultimately vital to the patients you serve.

*Baxter and Bio-Set are registered trademarks of Baxter International Inc., its subsidiaries or affiliates.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here